OBJECTIVES: This study sought to determine the effects of endogenous tetrahydrobiopterin (BH4) bioavailability on endothelial nitric oxide synthase (eNOS) coupling, nitric oxide (NO) bioavailability, and vascular superoxide production in patients with coronary artery disease (CAD). BACKGROUND: GTP-cyclohydrolase I, encoded by the GCH1 gene, is the rate-limiting enzyme in the biosynthesis of BH4, an eNOS cofactor important for maintaining enzymatic coupling. We examined the associations between haplotypes of the GCH1 gene, GCH1 expression and biopterin levels, and the effects on endothelial function and vascular superoxide production. METHODS: Blood samples and segments of internal mammary arteries and saphenous veins were obtained from patients with CAD undergoing coronary artery bypass grafting (n = 347). The GCH1 haplotypes were defined by 3 polymorphisms: rs8007267G<A, rs3783641A<T, and rs10483639C<G (X haplotype: A, T, G; O haplotype: any other combination). Vascular superoxide (+/- the eNOS inhibitor N(G)-nitro-L-arginine methyl ester [L-NAME]) was measured by lucigenin-enhanced chemiluminescence, whereas the vasorelaxations of saphenous veins to acetylcholine were evaluated ex vivo. RESULTS: Haplotype frequencies were OO 70.6%, XO 27.4%, and XX 2.0%. The X haplotype was associated with significantly lower vascular GCH1 messenger ribonucleic acid expression and substantial reductions in both plasma and vascular BH4 levels. In X haplotype carriers both vascular superoxide and L-NAME-inhibitable superoxide were significantly increased, and were associated with reduced vasorelaxations to acetylcholine. CONCLUSIONS: GCH1 gene expression, modulated by a particular GCH1 haplotype, is a major determinant of BH4 bioavailability both in plasma and in the vascular wall in patients with CAD. Genetic variation in GCH1 underlies important differences in endogenous BH4 availability and is a determinant of eNOS coupling, vascular redox state, and endothelial function in human vascular disease.
OBJECTIVES: This study sought to determine the effects of endogenous tetrahydrobiopterin (BH4) bioavailability on endothelial nitric oxide synthase (eNOS) coupling, nitric oxide (NO) bioavailability, and vascular superoxide production in patients with coronary artery disease (CAD). BACKGROUND:GTP-cyclohydrolase I, encoded by the GCH1 gene, is the rate-limiting enzyme in the biosynthesis of BH4, an eNOS cofactor important for maintaining enzymatic coupling. We examined the associations between haplotypes of the GCH1 gene, GCH1 expression and biopterin levels, and the effects on endothelial function and vascular superoxide production. METHODS: Blood samples and segments of internal mammary arteries and saphenous veins were obtained from patients with CAD undergoing coronary artery bypass grafting (n = 347). The GCH1 haplotypes were defined by 3 polymorphisms: rs8007267G<A, rs3783641A<T, and rs10483639C<G (X haplotype: A, T, G; O haplotype: any other combination). Vascular superoxide (+/- the eNOS inhibitor N(G)-nitro-L-arginine methyl ester [L-NAME]) was measured by lucigenin-enhanced chemiluminescence, whereas the vasorelaxations of saphenous veins to acetylcholine were evaluated ex vivo. RESULTS: Haplotype frequencies were OO 70.6%, XO 27.4%, and XX 2.0%. The X haplotype was associated with significantly lower vascular GCH1 messenger ribonucleic acid expression and substantial reductions in both plasma and vascular BH4 levels. In X haplotype carriers both vascular superoxide and L-NAME-inhibitable superoxide were significantly increased, and were associated with reduced vasorelaxations to acetylcholine. CONCLUSIONS:GCH1 gene expression, modulated by a particular GCH1 haplotype, is a major determinant of BH4 bioavailability both in plasma and in the vascular wall in patients with CAD. Genetic variation in GCH1 underlies important differences in endogenous BH4 availability and is a determinant of eNOS coupling, vascular redox state, and endothelial function in humanvascular disease.
Authors: J B Laursen; M Somers; S Kurz; L McCann; A Warnholtz; B A Freeman; M Tarpey; T Fukai; D G Harrison Journal: Circulation Date: 2001-03-06 Impact factor: 29.690
Authors: Jeffrey P Khoo; Lan Zhao; Nicholas J Alp; Jennifer K Bendall; Taija Nicoli; Kirk Rockett; Martin R Wilkins; Keith M Channon Journal: Circulation Date: 2005-04-11 Impact factor: 29.690
Authors: Jeffrey P Khoo; Taija Nicoli; Nicholas J Alp; Janice Fullerton; Jonathan Flint; Keith M Channon Journal: Mol Genet Metab Date: 2004-07 Impact factor: 4.797
Authors: Nicholas J Alp; Martina A McAteer; Jeffrey Khoo; Robin P Choudhury; Keith M Channon Journal: Arterioscler Thromb Vasc Biol Date: 2004-01-05 Impact factor: 8.311
Authors: Giovanni Ferrari; John Quackenbush; John Strobeck; Lan Hu; Christopher K Johnson; Andrew Mak; Richard E Shaw; Kathleen Sayles; Mariano E Brizzio; Alex Zapolanski; Juan B Grau Journal: Genomics Date: 2014-05-20 Impact factor: 5.736
Authors: Philip J Lupo; Claudia Chapa; Darryl Nousome; Cody Duhon; Mark A Canfield; Gary M Shaw; Richard H Finnell; Huiping Zhu Journal: Mol Genet Metab Date: 2012-09-25 Impact factor: 4.797
Authors: Shad B Smith; Ilkka Reenilä; Pekka T Männistö; Gary D Slade; William Maixner; Luda Diatchenko; Andrea G Nackley Journal: Pain Date: 2014-09-16 Impact factor: 6.961